-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) announced that the marketing application for savolitinib (savolitinib) for adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who failed to amplify the MET gene after at least 2 treatments has been accepted by China's State Drug Administration and included in priority review.

Zhitongcaijing·12/30/2025 10:09:08
Listen to the news
Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) announced that the marketing application for savolitinib (savolitinib) for adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who failed to amplify the MET gene after at least 2 treatments has been accepted by China's State Drug Administration and included in priority review.